LecTec and Endo Pharmaceuticals Come to Terms on Patent Dispute

Posted on: Tue, 17 Nov 2009 00:15:00 EST


Symbols: ENDP, LECT
Nov 17, 2009 (Close-Up Media via COMTEX) --
LECT | Quote | Chart | News | PowerRating -- LecTec Corp. (OTCBB: LECT | Quote | Chart | News | PowerRating) announced that it has reached a settlement with Endo Pharmaceuticals Inc. on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

In a release, the Company noted that Endo Pharmaceuticals has agreed to make a one-time, $23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. "LecTec is pleased to have reached an agreement with Endo Pharmaceuticals which avoids the uncertainties of litigation and provides LecTec with the capital to explore the opportunities in its patent portfolio," said Judd Berlin, chief executive officer of LecTec.

LecTec said that it filed a patent infringement action in U.S. District Court in July 2008 against Endo Pharmaceuticals and others in the topical medicated patch business alleging patent infringement of the core structure and composition claims of two of LecTec's patents.

LecTec Corp. is an intellectual property licensing and holding company.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Endo Pharmaceuticals Hld (ENDP) ENDP. Endo Pharmaceuticals Hld (ENDP) has Short Term PowerRatings at TradingMarkets. Details on Endo Pharmaceuticals Hld (ENDP) Short Term PowerRatings is available at This Link.

For full details on (LECT) LECT. (LECT) has Short Term PowerRatings at TradingMarkets. Details on (LECT) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.